Fischer agrees to give GE Tilt-C manufacturing rights

Article

Agreement is an apparent turnabout for GESometimes, the actions of the big and powerful are beyond the comprehension of mere mortals. One of those cases may have occurred last month, when GE Medical Systems agreed to swap stock for tilting C-arm

Agreement is an apparent turnabout for GE

Sometimes, the actions of the big and powerful are beyond the comprehension of mere mortals. One of those cases may have occurred last month, when GE Medical Systems agreed to swap stock for tilting C-arm technology developed by Fischer Imaging of Denver. The deal came after years of an on-again, off-again marketing relationship between the two firms that had an unsettling impact on Fischer’s financial results.

Fischer announced March 29 that GE would exchange 62% of its preferred stock in Fischer for the nonexclusive right to manufacture the company’s Tilt-C tilting C-arm system. The companies expect that the transfer of necessary technology will be completed by mid-April, although Fischer will continue to manufacture the units for GE through the end of 1999. The transaction will give Fischer a one-time gain of roughly $6 million.

The relationship between Fischer and GE regarding Tilt-C has been rocky since its inception. In 1994, the two firms agreed that Fischer would supply GE with Tilt-C and other products. A year later, as Fischer struggled with declining revenues, Milwaukee-based GE offered Fischer $10 million in an effort to bolster the troubled firm and ensure GE’s access to Tilt-C (SCAN 7/6/95). GE’s investment included the option of taking over manufacturing of Tilt-C in exchange for Fischer preferred stock, in the event of a hostile takeover at Fischer.

But despite its ostensible commitment to Tilt-C, the number of orders GE placed for the units dropped over the next two years. This contributed to a 50% decline in Fischer’s OEM sales that wreaked havoc on the company’s financial results (SCAN 8/6/97). GE’s decision to manufacture the systems is an apparent turnaround in its position on the product, but GE executives were unavailable for comment.

From Fischer’s standpoint, last month’s deal is part of its effort to refocus the company’s energies toward whole systems rather than components, according to Morgan Nields, chairman and CEO.

“Our focus is to deemphasize manufacturing components in subsystems for other OEMs,” Nields said. “Our interest is no longer in that line of business. We’re interested in manufacturing the entire system, as well as installing and servicing it. Our goal is to move our activities down the value chain, closer to the customer.”

Since the agreement isn’t exclusive, Fischer will continue to manufacture its version of Tilt-C, and retains the right to license the technology to other entities.

© 1999 Miller Freeman, Inc.All rights reserved.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.